HIV-1 protease inhibitors: effects on HIV-2 replication and resistance

Trends in Pharmacological Sciences

Volumn 29, Issue 1, 2008, Pages 42-49

  Menéndez Arias, Luis ^a   Tözsér, József ^b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ATAZANAVIR; DARUNAVIR; INDINAVIR; ISOLEUCINE; LEUCINE; LOPINAVIR; METHIONINE; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; BINDING SITE; CELL CULTURE; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; IC 50; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEINASE INHIBITION; REVIEW; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; VIRUS STRAIN;

BINDING SITES; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HIV-2; HUMANS; POLYMORPHISM, GENETIC; VIRUS REPLICATION;

EID: 37549038589     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.10.013     Document Type: Review

References (44)

1. Clavel F., et al. Isolation of a new retrovirus from West African patients with AIDS. Science 233 (1986) 343-346
2. Bock P.J., and Markovitz D.M. Infection with HIV-2. AIDS 15 Suppl. 5 (2001) S35-S45
3. Sebastian J., and Faruki H. Update on HIV resistance and resistance testing. Med. Res. Rev. 24 (2004) 115-125
4. Witvrouw M., et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9 (2004) 57-65
5. Palella Jr. F.J., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338 (1998) 853-860
6. Gustchina A., and Weber I.T. Comparative analysis of the sequences and structures of HIV-1 and HIV-2 proteases. Proteins 10 (1991) 325-339
7. Louis J.M., et al. HIV-1 protease: Structure dynamics, and inhibition. Adv. Pharmacol. 55 (2007) 261-298
8. Menéndez-Arias L. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucleic Acid Res. Mol. Biol. 71 (2002) 91-147
9. Colson P., et al. Polymorphism and drug selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J. Clin. Microbiol. 42 (2004) 570-577
10. Pieniazek D., et al. HIV-2 protease sequences of subtypes A and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. AIDS 18 (2004) 495-502
11. Damond F., et al. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J. Clin. Microbiol. 43 (2005) 484-487
12. Parreira R., et al. Natural polymorphisms of HIV type 2 pol sequences from drug naive individuals. AIDS Res. Hum. Retroviruses 22 (2006) 1178-1182
13. Ntemgwa M., et al. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51 (2007) 604-610
14. Ruelle J., et al. Genetic polymorphisms and resistance mutations of HIV type 2 in antiretroviral-naïve patients in Burkina Faso. AIDS Res. Hum. Retroviruses 23 (2007) 955-964
15. Ceccherini-Silberstein F., et al. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS 18 (2004) F11-F19
16. Tözsér J., and Oroszlan S. Proteolytic events of HIV-1 replication as targets for therapeutic intervention. Curr. Pharm. Des. 9 (2003) 1803-1815
17. Tözsér J., et al. Studies on the role of the S4 substrate binding site of HIV proteinases. FEBS Lett. 279 (1991) 356-360
18. Tözsér J., et al. Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases. Biochemistry 31 (1992) 4793-4800
19. Ghosh A.K., et al. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance. J. Med. Chem. 49 (2006) 5252-5261
20. King N.M., et al. Combating susceptibility to drug resistance: lessons from HIV-1 protease. Chem. Biol. 11 (2004) 1333-1338
21. Menéndez-Arias L. Targeting HIV: Antiretroviral therapy and development of drug resistance. Trends Pharmacol. Sci. 23 (2002) 381-388
22. Johnson V.A., et al. Update of the drug resistance mutations in HIV-1: 2007. Top. HIV Med. 15 (2007) 119-125
23. Yoshimura K., et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J. Virol. 76 (2002) 1349-1358
24. Koh Y., et al. Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro. Antimicrob. Agents Chemother. 47 (2003) 3123-3129
25. Descamps D., et al. In vitro phenotypic susceptibility of HIV-2 clinical isolates to protease inhibitors: amprenavir, atazanavir, lopinavir, and tipranavir. Antivir. Ther. 11 (2006) S103
26. th Conference on Retroviruses and Opportunistic Infections, February 25-28, Los Angeles, CA, U.S.A. Abstract no. 615 (http://www.retroconference.org/2007/Abstracts/29431.htm)
27. Gong Y.-F., et al. Atazanavir susceptibility spectrum extends to HIV-1 non-B subtypes and HIV-2 viral isolates. Antivir. Ther. 11 (2006) S100
28. Rodés B., et al. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. 57 (2006) 709-713
29. Doyon L., et al. Selection and characterization of HIV-1 showing reduced susceptibility to the non-peptidic protease inhibitor tipranavir. Antiviral Res. 68 (2005) 27-35
30. Patick A.K., et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40 (1996) 292-297
31. Masse S., et al. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob. Agents Chemother. 51 (2007) 3075-3080
32. Rodés B., et al. High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. AIDS 20 (2006) 127-129
33. Carrillo A., et al. In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J. Virol. 72 (1998) 7532-7541
34. Mo H., et al. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. 79 (2005) 3329-3338
35. Condra J.H., et al. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70 (1996) 8270-8276
36. Molla A., et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2 (1996) 760-766
37. Patick A.K., et al. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob. Agents Chemother. 42 (1998) 2637-2644
38. Masquelier B., et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46 (2002) 2926-2932
39. Rodés B., et al. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38 (2000) 1370-1374
40. Van der Ende M.E., et al. Clinical, immunological and virological response to different antiretroviral regimens in a cohort of HIV-2-infected patients. AIDS 17 Suppl. 3 (2003) S55-S61
41. Cavaco Silva J., et al. Mutations in HIV-2 protease selected by protease-inhibitor therapy. Antivir. Ther. 12 (2007) S87
42. Grossman Z., et al. Genotypic variation of HIV-1 reverse transcriptase and protease: comparative analysis of clade C and clade B. AIDS 15 (2001) 1453-1460
43. Garriga C., et al. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J. Med. Virol. 79 (2007) 1617-1628
44. Brandin E., et al. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res. Hum. Retroviruses 19 (2003) 543-550